mitomycin has been researched along with Diarrhea in 23 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
Excerpt | Relevance | Reference |
---|---|---|
"To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 9.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
"We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 9.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
"No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 9.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
"We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 9.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
"A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 7.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
"Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer." | 5.17 | Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013) |
"To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 5.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
"We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 5.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
"No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 5.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
"We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy." | 5.08 | Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer. ( Bokemeyer, C; Daikeler, T; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Müller, C; Seeber, S, 1998) |
"Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom." | 3.76 | Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. ( Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW, 2010) |
"A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 3.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
" We screened cancer patients' tumors for FA functional defects then aimed to establish the safety/feasibility of administering PARP inhibitors as monotherapy and combined with a DNA-breaking agent." | 2.82 | Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. ( Bekaii-Saab, T; Chen, A; Duan, W; Ji, J; Lustberg, M; Marshall, J; Rose, J; Schaaf, LJ; Shilo, K; Thurmond, J; Timmers, C; Villalona-Calero, MA; Westman, JA; Xiaobai, L; Zhao, W, 2016) |
" Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
" In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
"169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B)." | 2.72 | Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. ( Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N, 2006) |
"Twenty-one stomach cancer patients and 34 colorectal cancer patients were registered in the study." | 2.67 | [Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)]. ( Hachisuka, K; Honda, H; Honda, K; Maeda, A; Nakazato, H; Tsuruga, N; Yamaguchi, A; Yoshizaki, S; Yura, J, 1994) |
" Patient acute gastrointestinal toxicity was recorded using Common Terminology Criteria of Adverse Events (CTCAE) diarrhoea grading." | 1.48 | Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. ( Amor, H; Blakey, D; Chao, M; Guerrieri, M; Guiney, M; Ho, H; Macleod, C; Melven, L; Ng, M; Skelton, J; Subramanian, B, 2018) |
"Grade 3-4 neutropenia was seen in 10/23 patients (43%)." | 1.46 | PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. ( Beer, J; Bodis, S; Oehler, C; Vlachopoulou, V; von Moos, R; Zimmermann, M; Zwahlen, DR, 2017) |
"Mitomycin C suppository was significantly less toxic compared with intravenous delivery, and higher rectal tissue concentrations were observed from 10 to 30 minutes (P < 0." | 1.30 | Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. ( Ackerman, D; Galandiuk, S; Hofmeister, A; LaRocca, R; Lewis, RK; Myers, SR; Paris, KJ; Pokorny, RM; Wrightson, WR, 1997) |
" Pharmacokinetic examination after intravenous injection of low-dose MMC (0." | 1.29 | A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics. ( Boku, N; Ishii, H; Kaneko, K; Kusada, O; Muro, K; Muto, M; Ohkuwa, M; Ohtsu, A; Sasaki, Y; Tajiri, H; Yoshida, S, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (8.70) | 18.7374 |
1990's | 7 (30.43) | 18.2507 |
2000's | 6 (26.09) | 29.6817 |
2010's | 7 (30.43) | 24.3611 |
2020's | 1 (4.35) | 2.80 |
Authors | Studies |
---|---|
Lukovic, J | 3 |
Hosni, A | 3 |
Liu, A | 3 |
Chen, J | 3 |
Tadic, T | 3 |
Patel, T | 3 |
Li, K | 3 |
Han, K | 3 |
Lindsay, P | 3 |
Craig, T | 3 |
Brierley, J | 3 |
Barry, A | 3 |
Wong, R | 3 |
Ringash, J | 3 |
Dawson, LA | 3 |
Kim, JJ | 3 |
Zimmermann, M | 1 |
Beer, J | 1 |
Bodis, S | 1 |
von Moos, R | 1 |
Vlachopoulou, V | 1 |
Zwahlen, DR | 1 |
Oehler, C | 1 |
Ng, M | 1 |
Ho, H | 1 |
Skelton, J | 1 |
Guerrieri, M | 1 |
Guiney, M | 1 |
Chao, M | 1 |
Blakey, D | 1 |
Macleod, C | 1 |
Amor, H | 1 |
Subramanian, B | 1 |
Melven, L | 1 |
Deenen, MJ | 1 |
Dewit, L | 1 |
Boot, H | 1 |
Beijnen, JH | 1 |
Schellens, JH | 1 |
Cats, A | 1 |
Villalona-Calero, MA | 1 |
Duan, W | 1 |
Zhao, W | 1 |
Shilo, K | 1 |
Schaaf, LJ | 1 |
Thurmond, J | 1 |
Westman, JA | 1 |
Marshall, J | 1 |
Xiaobai, L | 1 |
Ji, J | 1 |
Rose, J | 1 |
Lustberg, M | 1 |
Bekaii-Saab, T | 1 |
Chen, A | 1 |
Timmers, C | 1 |
Kruth, J | 1 |
Nissen, J | 1 |
Ernst, T | 2 |
Kripp, M | 2 |
Lukan, N | 2 |
Merx, K | 2 |
Hofmann, WK | 1 |
Hochhaus, A | 2 |
Hofheinz, RD | 2 |
Tebbutt, NC | 1 |
Wilson, K | 1 |
Gebski, VJ | 1 |
Cummins, MM | 1 |
Zannino, D | 1 |
van Hazel, GA | 1 |
Robinson, B | 1 |
Broad, A | 1 |
Ganju, V | 1 |
Ackland, SP | 1 |
Forgeson, G | 1 |
Cunningham, D | 1 |
Saunders, MP | 1 |
Stockler, MR | 1 |
Chua, Y | 1 |
Zalcberg, JR | 1 |
Simes, RJ | 1 |
Price, TJ | 1 |
Shabaruddin, FH | 1 |
Elliott, RA | 1 |
Valle, JW | 1 |
Newman, WG | 1 |
Payne, K | 1 |
Di Bartolomeo, M | 1 |
Buzzoni, R | 1 |
Mariani, L | 1 |
Ferrario, E | 1 |
Katia, D | 1 |
Gevorgyan, A | 1 |
Zilembo, N | 1 |
Bordonaro, R | 1 |
Bochicchio, AM | 1 |
Massidda, B | 1 |
Ardizzoia, A | 1 |
Ardizzoni, A | 1 |
Marini, G | 1 |
Aitini, E | 1 |
Schieppati, G | 1 |
Comella, G | 1 |
Pinotti, G | 1 |
Palazzo, S | 1 |
Cicero, G | 1 |
Bajetta, E | 1 |
Villa, E | 1 |
Fagnani, D | 1 |
Reguzzoni, G | 1 |
Agostana, B | 1 |
Oliani, C | 1 |
Kildani, B | 1 |
Duro, M | 1 |
Botta, M | 1 |
Mozzana, R | 1 |
Mantovani, G | 1 |
Gnad-Vogt, U | 1 |
Schultheis, B | 1 |
Glynne-Jones, R | 1 |
Meadows, H | 1 |
Wan, S | 1 |
Gollins, S | 1 |
Leslie, M | 1 |
Levine, E | 1 |
McDonald, AC | 1 |
Myint, S | 1 |
Samuel, L | 1 |
Sebag-Montefiore, D | 1 |
Inokuchi, K | 1 |
Hattori, T | 1 |
Taguchi, T | 1 |
Abe, O | 1 |
Ogawa, N | 1 |
Nakata, E | 1 |
Okajima, K | 1 |
Ishida, Y | 1 |
Munetomo, Y | 1 |
Gotoh, K | 1 |
Toyohara, M | 1 |
Miyazaki, H | 1 |
Matsunaga, S | 1 |
Maeura, Y | 1 |
Fujimura, T | 1 |
Francini, G | 1 |
Petrioli, R | 1 |
Aquino, A | 1 |
Gonnelli, S | 1 |
Conti, JA | 1 |
Kemeny, NE | 1 |
Saltz, LB | 1 |
André, AM | 1 |
Grossano, DD | 1 |
Bertino, JR | 1 |
Yamaguchi, A | 1 |
Maeda, A | 1 |
Hachisuka, K | 1 |
Yura, J | 1 |
Honda, K | 1 |
Honda, H | 1 |
Yoshizaki, S | 1 |
Tsuruga, N | 1 |
Nakazato, H | 1 |
Boku, N | 1 |
Ohtsu, A | 1 |
Muro, K | 2 |
Kaneko, K | 1 |
Muto, M | 1 |
Ohkuwa, M | 1 |
Ishii, H | 1 |
Sasaki, Y | 1 |
Tajiri, H | 1 |
Yoshida, S | 1 |
Kusada, O | 1 |
Pokorny, RM | 1 |
Wrightson, WR | 1 |
Lewis, RK | 1 |
Paris, KJ | 1 |
Hofmeister, A | 1 |
LaRocca, R | 1 |
Myers, SR | 1 |
Ackerman, D | 1 |
Galandiuk, S | 1 |
Hartmann, JT | 1 |
Harstrick, A | 1 |
Daikeler, T | 1 |
Kollmannsberger, C | 1 |
Müller, C | 1 |
Seeber, S | 1 |
Kanz, L | 1 |
Bokemeyer, C | 1 |
Sobrero, A | 1 |
Guglielmi, A | 1 |
Cirillo, M | 1 |
Recaldin, E | 1 |
Frassineti, GL | 1 |
Aschele, C | 1 |
Ravaioli, A | 1 |
Testore, P | 1 |
Caroti, C | 1 |
Gallo, L | 1 |
Pessi, MA | 1 |
Cortesi, E | 1 |
Turci, D | 1 |
Grossi, F | 1 |
Labianca, R | 1 |
Valentini, V | 1 |
Coco, C | 1 |
Cellini, N | 1 |
Picciocchi, A | 1 |
Fares, MC | 1 |
Rosetto, ME | 1 |
Mantini, G | 1 |
Morganti, AG | 1 |
Barbaro, B | 1 |
Cogliandolo, S | 1 |
Nuzzo, G | 1 |
Tedesco, M | 1 |
Ambesi-Impiombato, F | 1 |
Cosimelli, M | 1 |
Rotman, M | 1 |
Yamao, T | 1 |
Shirao, K | 1 |
Matsumura, Y | 1 |
Yamada, Y | 1 |
Goto, M | 1 |
Chin, K | 1 |
Shimada, Y | 1 |
Becouarn, Y | 1 |
Calabet, J | 1 |
Brunet, R | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250] | Phase 2 | 264 participants (Actual) | Interventional | 2019-11-28 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
15 trials available for mitomycin and Diarrhea
Article | Year |
---|---|
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 2013 |
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; | 2016 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2006 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2008 |
Postoperative adjuvant chemotherapy for gastric carcinoma. Analysis of data on 1805 patients followed for 5 years.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Moda | 1984 |
[Combination therapy of high dose 5'-DFUR+MMC for advanced or recurrent gastric cancer. 5'-DFUR Joint Research Group in the Osaka District for Gastric Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; | 1995 |
Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
[Study of 5'-DFUR treatment as postoperative adjuvant chemotherapy for stomach and colorectal cancer. Tokai GATS Group (pilot study)].
Topics: Administration, Oral; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; | 1994 |
Phase II study of continuous 120 h infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Colorectal Neoplasms; Diarrhea; Disease Progressio | 1998 |
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D | 2001 |
Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response R | 2001 |
8 other studies available for mitomycin and Diarrhea
Article | Year |
---|---|
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2017 |
Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Topics: Abdominal Cavity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; An | 2018 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; | 2010 |
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Evalua | 1993 |
A case of advanced gastric cancer complicated by severe toxicity induced by a combination of tegafur, uracil and mitomycin C, and associated with abnormal pharmacokinetics.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow Diseas | 1996 |
Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer.
Topics: Adenocarcinoma; Administration, Rectal; Animals; Antibiotics, Antineoplastic; Chromatography, High P | 1997 |
Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Colonic Neoplasms; Diarrhea; D | 1988 |